APOBEC, a prominent mutational signature in oncogenesis, initiates from the activity of the A3A & A3B cytosine deaminases. In this original article, investigators studied its association with RTK-driven lung cancer 🫁 including resistance to treatments💊 annalsofoncology.org/article/S0923-…

EVERY week should be post-doc appreciation week – but here it is. Some of this crew is beyond post-doc, on faculty, but included here as essential to the functioning of our lab. Thank you all for all you do! MSK ScienceEducation

ICYMI at #WCLC22: Presenters discussed optimizing the management of SCLC and neuroendocrine tumors. Read a recap in ILCN: ow.ly/RZO650KLuG7 @alvaroquintanal #LCSM

Out today — great work defining the role of CD39+ CD8 T cells in anti-cancer immunity led by Andrew Chow with key support from Taha, Jedd Wolchok, and many others. authors.elsevier.com/a/1gJgV3qNrUqG…

Pts with EGFR-mutant lung CA rarely benefit from immunoRX. But for those who want, without giving up TKI — combo with erlotinib (NOT osi!) appears feasible. I have at least one patient who started on this in 2014, still responding. Every pt is an N of 1! authors.elsevier.com/sd/article/S20…

🎉 Join Charlie Rudin & Ticiana Batista (Leal) for the FIRST ANNUAL #SCLCYIF, in collaboration w/ LUNGevity Foundation!🔬 Improve your research skills, evaluate peers' work & enhance your career as an #SCLC researcher! Submit Abstracts by May 19➡️➡️➡️ ce.ceconcepts.com/sclc-23 #Oncology #MedTwitter

Is sciencetwitter still a thing? Maybe... Really happy to see this one out in press; the very talented Janneke Jaspers demonstrates efficacy of an anti-DLL3 IL-18-armored CAR-T against small cell lung cancer. jci.org/articles/view/…

Happy to see our work on CD39+ CD8+ T cells in human lung cancer being profiled by EACR ! Charlie Rudin Jedd Wolchok Taha Memorial Sloan Kettering Cancer Center

Why aren’t most small cell lung cancers more responsive to immunotherapy? Epigenetic silencing of antigen presentation might be one key — and targetable — solution. Data from BMS CheckMate 032. jto.org/article/S1556-…

DLL3 is the target of multiple investigational therapeutic strategies for patients with SCLC and other high-grade NE cancers. A pleasure to review state-of-the-state together with many clinical leaders of the field. jhoonline.biomedcentral.com/articles/10.11…

So excited, our phase 1/2 first in human imaging w/ [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate, is out. JT Poirier Charlie Rudin Jason Lewis Radiochem MSK Salomon Tendler Michael Morris Lisa Bodei, MD, PhD et al., sciencedirect.com/science/articl…

Inspiration for the August cover art: First-in-human trial of #imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade #neuroendocrinetumours of the lung and prostate thelancet.com/journals/lanon… #NeuroendocrineTumors #SCLC

Now online in Cancer Discovery: #Chromothripsis-mediated Small Cell Lung Carcinoma - by Natasha Rekhtman MD PhD Sam T Christopher Febres-Aldana, MD Charlie Rudin and colleagues doi.org/10.1158/2159-8… Memorial Sloan Kettering Cancer Center #SCLC

1 Hot off the press from team Memorial Sloan Kettering Cancer Center in Cancer Discovery! A study solving the puzzle of exceptional new lung cancer type: #Chromothripsis-mediated Small Cell Lung Cancer #SCLC This took nearly a decade and 42 coauthors to unravel. Here are some highlights 👇